PIK3CA and thyroid gland papillary carcinoma: Previous studies have shown that the combination of SB590885 and the AKT inhibitor ZSTK474 impacted the proliferation of papillary thyroid cancer cell lines by inhibiting the ERK MAPK and PI3K/AKT signalling pathways [19, 22].